Stock RVX RESVERLOGIX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Resverlogix Corp.

Equities

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:06:29 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.06 CAD +9.09% Intraday chart for Resverlogix Corp. +9.09% -14.29%
Apr. 01 Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 21 Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 465 199.4 173.2 98 27.41 14.37
Enterprise Value (EV) 1 519.6 343.9 212.7 155.7 77.56 85.32
P/E ratio -5.69 x -1.09 x 66 x -3.91 x -7.6 x -0.85 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -12.6 x -8.95 x -15 x -10 x -7.07 x -17.7 x
EV / FCF -49.3 x 23.4 x -3.33 x -18.2 x 129 x 31 x
FCF Yield -2.03% 4.27% -30% -5.51% 0.77% 3.22%
Price to Book -5.1 x -0.91 x -4.35 x -1.64 x -0.46 x -0.19 x
Nbr of stocks (in thousands) 193,050 210,710 234,739 242,969 265,466 272,171
Reference price 2 2.409 0.9462 0.7380 0.4034 0.1033 0.0528
Announcement Date 7/30/18 7/29/19 3/31/21 3/31/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -41.23 -38.41 -14.2 -15.52 -10.96 -4.822
EBIT 1 -41.56 -38.74 -14.57 -15.94 -11.43 -5.178
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -58.26 -162.8 2.496 -24.76 -3.592 -16.73
Net income 1 -58.31 -162.8 2.464 -24.77 -3.61 -16.74
Net margin - - - - - -
EPS 2 -0.4233 -0.8655 0.0112 -0.1033 -0.0136 -0.0620
Free Cash Flow 1 -10.54 14.67 -63.85 -8.576 0.5996 2.749
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/30/18 7/29/19 3/31/21 3/31/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 54.6 144 39.5 57.7 50.2 70.9
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.324 x -3.761 x -2.779 x -3.721 x -4.574 x -14.71 x
Free Cash Flow 1 -10.5 14.7 -63.8 -8.58 0.6 2.75
ROE (net income / shareholders' equity) 63% 112% -86.8% 49.7% 6.06% 25%
ROA (Net income/ Total Assets) -271% -197% -99.2% -96.3% -79% -44.2%
Assets 1 21.49 82.58 -2.484 25.72 4.571 37.85
Book Value Per Share 2 -0.4700 -1.040 -0.1700 -0.2500 -0.2200 -0.2700
Cash Flow per Share 2 0 0.0400 0 0 0 0
Capex - 0.01 0.01 - - -
Capex / Sales - - - - - -
Announcement Date 7/30/18 7/29/19 3/31/21 3/31/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RESVERLOGIX CORP. Stock Resverlogix Corp.
-14.29% 12.03M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RVX Stock
  4. Financials Resverlogix Corp.